United Kingdom · Question · Written question
UIN 62829
Restless Legs Syndrome: Medical Treatments
Original
Introduced
25 June 2025
Last action
3 July 2025 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
3 July 2025
Summary
To ask the Secretary of State for Health and Social Care, what assessment NHS England has made of the potential risks of dopamine agonists as a treatment for restless leg syndrome.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
25 June 2025
Written question
To ask the Secretary of State for Health and Social Care, what assessment NHS England has made of the potential risks of dopamine agonists as a treatment for restless leg syndrome.
Source: Commons
3 July 2025
Answer
NHS England has made no assessment. The Medicines and Healthcare products Regulatory Agency (MHRA) assesses all medicines before they are licensed in the United Kingdom, with regard to quality, safety, and efficacy. The licensed dopamine agonist medicines...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2025-06-25/62829
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1816554
- uk · wq-1816554 · source updated 3 July 2025